Evidence map›Paper›PMID 41419662›Full record

ArticleCommunications biology2025

RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination.

Michael Gruet, Yitao Xu, Lyutong An, Yurui Ma, Cristina Balcells, Katie Tyson, Laila C Evangelista, Sarah Spear, Yuewei Xu, Flora McKinney and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Michael Gruet *Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-6074-7163
Yitao Xu *Department of Surgery and Cancer, Imperial College London, London, UK.
Lyutong AnDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0009-0007-1581-7979
Yurui MaDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-8943-9287
Cristina BalcellsDepartment of Surgery and Cancer, Imperial College London, London, UK.
Katie TysonDepartment of Surgery and Cancer, Imperial College London, London, UK.
Laila C EvangelistaDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0009-0003-5551-9897
Sarah SpearDepartment of Surgery and Cancer, Imperial College London, London, UK.
Yuewei XuDepartment of Surgery and Cancer, Imperial College London, London, UK.
Flora McKinneyDepartment of Surgery and Cancer, Imperial College London, London, UK.
Julia BabutaDepartment of Metabolism, Digestion and Reproduction, Burlington Danes, Imperial College London, London, UK.
Chandler BrayDepartment of Surgery and Cancer, Imperial College London, London, UK.
Chiharu WickremesingheDepartment of Surgery and Cancer, Imperial College London, London, UK.
Alexandros P SiskosDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-5635-7426
Anke M NijhuisDepartment of Surgery and Cancer, Imperial College London, London, UK.
Edward W TateDepartment of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-2213-5814
Iain A McNeishDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-9387-7586
Adrian BenitoDepartment of Surgery and Cancer, Imperial College London, London, UK. a.benito-mauricio@imperial.ac.uk.
Hector C KeunDepartment of Surgery and Cancer, Imperial College London, London, UK. h.keun@imperial.ac.uk.ORCID http://orcid.org/0000-0001-7358-8851

Funding

RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/S023518/1
6 · The paper itself

Abstract

The combination of PARP and NAMPT inhibitors (PARPi/NAMPTi) has been explored for the treatment of triple-negative breast cancer, Ewing sarcoma and high-grade serous carcinoma (HGSC). However, dose limiting toxicity has hampered NAMPTi in clinical trials. To maximise the therapeutic window, we set out to identify predictive genomic biomarkers. Bioinformatic analysis and screening of a panel of epithelial ovarian cancer (EOC) cell lines revealed that cells with RAS/PI3K pathway mutations are sensitive to the NAMPTi FK866. Combined exposure to olaparib and FK866 is associated with a reduction in nicotinamide mononucleotide (NMN) and the PARP substrate nicotinamide adenine dinucleotide (NAD

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialMutationNicotinamide PhosphoribosyltransferaseOvarian NeoplasmsPhosphatidylinositol 3-KinasesPoly(ADP-ribose) Polymerase Inhibitorsras ProteinsAcrylamidesAnimalsApoptosisCell Line, TumorCytokinesFemaleHumansMiceAcrylamidesCytokinesN-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamideNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, humanolaparibPhosphatidylinositol 3-KinasesPhthalazinesPiperazinesPiperidinesPoly(ADP-ribose) Polymerase Inhibitorsras Proteins

Identifiers

PMID41419662
PMCPMC12764903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.